MedTrace Logo

Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors

NCT00436761 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-12-18

No results posted yet for this study

Summary

RATIONALE: Giving chemotherapy before a donor umbilical cord blood stem cell transplant helps stop the growth of tumor cells. It also helps stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood. The donated stem cells may replace the patient's immune cells and help destroy any remaining tumor cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and methylprednisolone after the transplant may stop this from happening.

PURPOSE: This phase I trial is studying the side effects of busulfan, melphalan, and antithymocyte globulin followed by umbilical cord blood transplant in treating young patients with refractory or relapsed malignant solid tumors.

Conditions

  • Unspecified Childhood Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

graft-versus-tumor induction therapy

BIOLOGICAL

sargramostim

DRUG

busulfan

DRUG

cyclosporine

DRUG

melphalan

DRUG

methylprednisolone

OTHER

flow cytometry

OTHER

immunologic technique

OTHER

laboratory biomarker analysis

PROCEDURE

allogeneic hematopoietic stem cell transplantation

PROCEDURE

umbilical cord blood transplantation

Sponsors & Collaborators

  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • Kenneth G. Lucas, MD · Milton S. Hershey Medical Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00436761 on ClinicalTrials.gov